Table 3.
Bone marrow evaluations.
| N (%) | |||
|---|---|---|---|
| BMA/BMP due to cytopenia | 118 (100%) | ||
| Type of assessment | Cytology | 107 (91%) | |
| Histopathology | 107 (91%) | ||
| Immunology | 64 (54%) | ||
| Cytogenetics | 5 (4%) | ||
| Molecular genetics | 3 (3%) | ||
| Cytologic signs of dysplasia | yes | 17 (14%) | |
| Erythropoiesis | 13 (11%) | ||
| Megakaryopoiesis | 8 (7%) | ||
| Granulopoiesis | 4 (3%) | ||
| no | 90 (76%) | ||
| Assessment | Cytology | Normal | 47 (40%) |
| Unspecific/reactive | 31 (26%) | ||
| Hyperplastic myelopoiesis | 12 (10%) | ||
| Hypoplastic myelopoiesis | 7 (6%) | ||
| Myelodysplasia without MDS | 6 (5%) | ||
| Suspected lymphoma | 2 (2%) | ||
| MDS | 1 (1%) | ||
| Histopathology | Normal | 20 (17%) | |
| Unspecific/reactive | 74 (63%) | ||
| Hyperplastic myelopoiesis | 5 (4%) | ||
| Hypoplastic myelopoiesis | 2 (2%) | ||
| Myelodysplasia without MDS | 3 (3%) | ||
| Maturation defect | 2 (2%) | ||
| Immunology | Normal | 56 (47%) | |
| Unspecific/reactive | 4 (3%) | ||
| Suspected lymphoma | 3 (3%) | ||
| Cytogenetics | Normal | 5 (4%) | |
| Molecular genetics | Normal | 3 (3%) | |
| Final diagnosis | No new diagnosis | 117 (99%) | |
| MDS | 1 (1%) |
Count data is shown. BMA, bone marrow aspiration; BMB, bone marrow biopsy; MDS, myelodysplastic syndrome.